Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK would share additional data with U.S. agencies by the end of this year, she said. Citing the U.S. agency's decision, GSK cut its forecast for 2024 vaccine sales.
October 4, 2024 at 2:31 PM. GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report. The U.S. government has granted $72 million to European pharma giants GSK ...
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It also expects its 2024 sales to rise in ...
The ex-dividend date is the first date following the declaration of a dividend on which the buyer of a stock is not entitled to receive the next dividend payment. For calculation purposes, the number of days of ownership includes the day of disposition but not the day of acquisition. In the case of preferred stock, you must have held the stock ...
Andrew Witty. Sir Andrew Philip Witty (born 22 August 1964) [1] is a British business executive, who is the chief executive officer (CEO) of UnitedHealth Group. He was the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.
Walmsley said the company will submit data for U.S. approval for the vaccine to be used for 50-59 year olds by the end of the year. GSK is betting on Arexvy to be its next blockbuster medicine as ...